Medication
Jamp Temozolomide
DIN 02516845 · Jamp Pharma Corporation Likely a generic
What it is
- Active ingredients
- Temozolomide — 250 mg
- Form and route
- Capsule · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2022-07-26
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Ontario Drug Benefit coverage
As of 31 July 2026General benefit Part III-A
Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.
- What ODB pays per unit
- $97.5010
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 250mg Cap and will substitute one for another at a pharmacy counter in Ontario.
- Taro-Temozolomide 02443554Taro Pharmaceuticals Inc
- Temodal 02241096Merck Canada Inc
- Teva-Temozolomide 02395312Teva Canada Limited
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Antineoplastic and immunomodulating agents
- ATC code
- L01AX03
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of L01AX03, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.